Results of extraordinary general meeting in Pharma Equity Group A/S

 | Source: Pharma Equity Group A/S Pharma Equity Group A/S

  
  
 Results of extraordinary general meeting in Pharma Equity Group A/S
  

3 June 2024
Company announcement no. 19

 

Pharma Equity Group A/S today held an extraordinary general meeting with the following results:

 

  1. The company's share capital will be reduced by a nominal value of DKK 920,667,494.70 from a nominal value of DKK 1,022,963,883.00 to a nominal value of DKK 102,296,388.30 by allocation to a specific reserve pursuant to section 188(1)(3) of the Danish Companies Act. The capital reduction will be made by a proportional reduction of the denomination of all the company's shares, meaning that the denomination of the shares will be reduced from DKK 1.00 to DKK 0.1.
 

Prior to the completion of the capital reduction, the company's creditors will be encouraged to give notice on any claims against the company for a period of four weeks. The request will be published in the Danish Business Authority's IT-system.

 

  1. The chair of the general meeting was, with a right of substitution, authorised to file the resolution adopted with the Danish Business Authority and to make any such amendments as the Danish Business Authority may require to register or approve the resolution adopted.
 

 

For further information, please contact:

 
 Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114

Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222
  

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

 

 

Attachment


Pièces jointes

Announcement no. 19 UK